Ajanta Pharma gets US FDA observations after inspection at Dahej facility
United States Food and Drug Administration issued Form 483 to Ajanta Pharma limited after the successful completion of its audit of Ajanta Pharma's Dahej facility26-06-2023
26-06-2023
AJANTA PHARMA LTD. - 532331 - US FDA Inspection Of Our Dahej Facility
This is to inform you that our formulation facility at Dahej was inspected by US FDA from 19th June 2023 to 23rd June 2023. At the end of inspection, no Form 483 was issued to us.26-06-2023
AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 23, 2023 for Ravi Agrawal, trustee Ravi Agrawal Trust23-06-2023
Ajanta Pharma hits 52-week high on upbeat branded generic business outlook
The management is confident to scale up margins again in the coming years on the back of enhanced contribution from Branded Generics business and normalisation of freight costs22-06-2023
AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the Listing Regulations, please find enclosed notice published in newspapers regarding e-voting information for the 44th Annual General Meeting of the Company in terms of Section 108 of the Companies Act, 2013 read with Rule 20 of Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in the following newspapers on 17th June 2023: 1. Mumbai edition of Free Press Journal; 2. Mumbai edition of Navshakti.19-06-2023
Ajanta Pharma: Here is why the stock can be accumulated on dips
The company continues to remain on a good footing in branded business17-06-2023
AJANTA PHARMA LTD. - 532331 - Notice Of The 44Th Annual General Meeting (AGM) & Annual Report 2022-23
In compliance with the Companies Act 2013, rules framed thereunder and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, please find enclosed Notice convening the 44th AGM of shareholders and the Annual Report 2022-2316-06-2023
AJANTA PHARMA LTD. - 532331 - Reg. 34 (1) Annual Report.
We hereby inform that the Forty-Fourth Annual General Meeting ('AGM') of the Company will be held on Tuesday, 18th July 2023 at 11.00 a.m. through Video Conferencing or Other Audio-Visual Means. Pursuant to Regulation 34(1) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Annual Report and Business Responsibility & Sustainability Report of the Company for the financial year 2022-23 along with Notice of the AGM. The Annual report, Business Responsibility & Sustainability Report and the Notice of AGM are being sent through electronic mode to members whose e-mails ids are registered and the same are also uploaded on the Company''s website www.ajantapharma.com/ajanta/Investors/annual_results/?year=2022-23.16-06-2023
AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the Listing Regulations, please find enclosed notice published in newspapers in terms of Circular No. 20/2020 dated 5th May 2020 issued by Ministry of Corporate Affairs, inter-alia, intimating that 44th Annual General Meeting of the Company will be held on 18th July 2023 through Video Conferencing/Other Audio-Visual Means, in the following newspapers: a) Mumbai edition of Free Press Journal; b) Mumbai edition of Navshakti.14-06-2023
AJANTA PHARMA LTD. - 532331 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI Listing Regulations, we would like to inform you that Registrar and Transfer Agent of Company, M/s. Link Intime India Private Limited has received intimation for loss of share certificate and request for issuance of duplicate share certificate from a Shareholder.01-06-2023